Amjad Ahmed Aljagthmi

Dr. Amjad Aljaghtmi is a Postdoctoral Fellow specializing in translational stem cell research for cardiac diseases. Her work focuses on human pluripotent stem cell–derived cardiomyocyte and cardiac organoid models to elucidate disease mechanisms, enable drug discovery, and assess therapeutic responses. She integrates advanced differentiation platforms with molecular, functional, and biomarker analyses to maximize clinical relevance. In parallel, she has experience in biomarker discovery using patient-derived samples, including in cancer, with a background in cancer biology that supports cross-disease insights and precision medicine.

Human pluripotent stem cell differentiation for disease modelling

Cardiac disease modelling and therapeutic evaluation

Stem cell-based drug discovery platforms

Translational biomarker discovery using liquid biopsies

Molecular and epigenetic regulation of cell fate in disease

Translational regenerative medicine

Dr. Aljagthmi completed her PhD in Molecular Genetics and Cell Biology at Wright State University, USA, where she conducted mechanistic cancer biology research with direct relevance to cell fate regulation. Her doctoral work identified microRNA-320a as a tumor suppressor regulated by p63, a key regulator of epithelial stem cell maintenance and differentiation, and elucidated signaling pathways controlling cell migration and invasion, including PKCγ-mediated Rac1 activation. She also led a translational project examining the role of p63 and ERK3 kinase in gene regulation using patient-derived specimens from individuals with psoriasis.

She then joined the Stem Cell and Disease Laboratory at King Abdullah University of Science and Technology as a postdoctoral fellow, focusing on human pluripotent stem cell–based models to study transcriptional/epigenetic dysregulation in Klinefelter syndrome. She later pursued hospital-based postdoctoral training integrating pluripotent stem cell differentiation with disease modeling, drug discovery, and translational biomarker discovery to support clinically relevant therapeutic development.